UCB lands FDA ap­proval in newest in­di­ca­tion for new­ly-ac­quired Zo­genix epilep­sy drug

Three weeks af­ter Bel­gian phar­ma UCB fi­nal­ized its $1.9 bil­lion ac­qui­si­tion of Cal­i­for­nia-based biotech Zo­genix, its new­ly-ac­quired epilep­sy drug fen­flu­ramine got the seal of ap­proval …

Endpoints News

Sign up to read this article for free.

Get free access to a limited number of articles, plus choose newsletters to get straight to your inbox.